BRAF and hairy cell leukemia: Considering the favorable PFS and feasible drug tolerability in heavily pretreated HCL patients, ibrutinib may serve as a valuable therapeutic alternative when chemo(immuno)therapy is not an option and/or in BRAF wildtype HCL.